BRIDGenomics

Executive Summary

BRIDGenomics is a specialized consulting firm that provides strategy and 'visioneering' services for the development and commercialization of molecular diagnostics and genomic assays. Founded in 2015 and headquartered in San Diego, the company leverages over 20 years of combined industry experience to bridge technical, regulatory, and market gaps for its clients. BRIDGenomics focuses on next-generation sequencing (NGS) and advanced sequencing technologies, acting as an advisor to diagnostic developers, pharmaceutical companies, and laboratories. The firm helps clients navigate partnerships, outsourcing, and regulatory pathways, positioning itself as a key enabler in the rapidly evolving precision medicine landscape. Despite being a private, non-dilutive consulting business, BRIDGenomics plays a critical role in accelerating the translation of genomic innovations into clinical practice. Its deep domain expertise and client-centric approach make it a valuable partner for stakeholders seeking to overcome barriers in assay development and commercialization.

Upcoming Catalysts (preview)

• H2 2026Strategic partnership with a top-tier diagnostic company to co-develop an NGS-based liquid biopsy assay60% success
• Q1 2027Launch of a new service offering focused on regulatory strategy for FDA clearance of genomic tests50% success
• Q3 2026Hiring of a senior industry executive to lead expansion into pharmaceutical partnerships40% success